Introduction: clinical guidelines recommend to identify and treat people at high risk of fracture. Methods: we have carried out a simulation concerning pharmaco-economic issues in the treatment of severe osteoporosis and particularly those people with previous femoral fragility fractures, assuming that only 13.1% of hip fractured patients had started a proper antifracture therapy, as shown by the analysis of the Tuscany regional database. Results: Annual costs sustained by the Italian healthcare system for treating hip fractured patients all over Italy have been estimated to range from 2 560 000 in year 2000 to 3 291 750 in year 2005, representing only 0,3% of the overall costs sustained because of hip fractures in Italy. Conclusions: Sixty percent of the pharmacological costs can be considered as ineffective from a therapeutic point of view because patients were assuming their drugs only for 6 months. There is a need for specific codification of osteoporotic fragility fractures at hospital admissions and for implementing regional strategies aimed to reduce hip re-fractures by increasing the number of patients on treatment and incrementing adherence to treatment.

Piscitelli, P., Chitano, G., Greco, M., Benvenuto, M., Sbenaglia, E., Colì, G., et al. (2010). Pharmaco-economic issues in the treatment of severe osteoporosis. CLINICAL CASES IN MINERAL AND BONE METABOLISM, 7(1), 61-64.

Pharmaco-economic issues in the treatment of severe osteoporosis

TARANTINO, UMBERTO;
2010-01-01

Abstract

Introduction: clinical guidelines recommend to identify and treat people at high risk of fracture. Methods: we have carried out a simulation concerning pharmaco-economic issues in the treatment of severe osteoporosis and particularly those people with previous femoral fragility fractures, assuming that only 13.1% of hip fractured patients had started a proper antifracture therapy, as shown by the analysis of the Tuscany regional database. Results: Annual costs sustained by the Italian healthcare system for treating hip fractured patients all over Italy have been estimated to range from 2 560 000 in year 2000 to 3 291 750 in year 2005, representing only 0,3% of the overall costs sustained because of hip fractures in Italy. Conclusions: Sixty percent of the pharmacological costs can be considered as ineffective from a therapeutic point of view because patients were assuming their drugs only for 6 months. There is a need for specific codification of osteoporotic fragility fractures at hospital admissions and for implementing regional strategies aimed to reduce hip re-fractures by increasing the number of patients on treatment and incrementing adherence to treatment.
2010
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/33 - MALATTIE APPARATO LOCOMOTORE
English
Senza Impact Factor ISI
osteoporosis; fractures; costs
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898009/?tool=pmcentrez
Piscitelli, P., Chitano, G., Greco, M., Benvenuto, M., Sbenaglia, E., Colì, G., et al. (2010). Pharmaco-economic issues in the treatment of severe osteoporosis. CLINICAL CASES IN MINERAL AND BONE METABOLISM, 7(1), 61-64.
Piscitelli, P; Chitano, G; Greco, M; Benvenuto, M; Sbenaglia, E; Colì, G; Migliore, A; Granata, M; Iolascon, G; Gimigliano, R; Baggiani, A; Distante,...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/12122
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? ND
social impact